Introduction to FDA’s Division of Neurological and Physical Medicine Devices
AANS Abbreviated Slide Deck
Coming Soon
AANS FDA Session 2018
Patients in the U.S. have access to high-quality, safe, and effective medical devices of public health importance first in the world.

The U.S. is the world’s leader in regulatory science, medical device innovation and manufacturing, and radiation-emitting product safety.

U.S. post-market surveillance quickly identifies poorly performing devices, accurately characterizes real-world performance, and facilitates device approval or clearance.

Devices are legally marketed in the U.S. and remain safe, effective, and of high-quality.

Consumers, patients, their caregivers, and providers have access to understandable science-based information about medical devices and use this information to make health care decisions.
Experience in Moving Neurological Medical Devices From Bench to Market

- Clot Retriever for Ischemic Stroke
- Ablation Therapy
- Cognitive Function following concussion
- Prosthetic Arm
- Medical Device for Migraine
- Microcatheters for the neurovasculature
Medical Device Definition

Section 201(h) of the Federal Food, Drug and Cosmetic Act (21 U.S.C. 321) states, in part:

- “Device… means an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including any component, part, or accessory, which is…”

- “…intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man…” or

- “…intended to affect the structure or any function of the body of man and which does not achieve any of its primary intended purposes through chemical action….”
A Risk Based Approach for Medical Devices since 1976

Increasing Risk
Classification determines extent of regulatory control (Risk Based)

Class I
- General Controls

Class II
- General controls
- Special controls

Class III
- General controls
- Premarket approval (PMA)

General Controls
- Electronic Establishment Registration
- Electronic Device Listing
- Quality Systems
- Labeling
- Medical Device Reporting (MDR)
- Premarket Notification [510(k)] (unless exempt)

Special Controls (addressing Risk)
- Guidelines (e.g., Glove Manual)
- Mandatory Performance Standard
- Performance testing, such as biocompatibility, engineering, animal, etc.
- Special Labeling
Classifications & Regulatory Pathways

• Class III: generally PMA (Premarket Approval)
• Class II: 510(k) (premarket notification), if the intended use and technology are similar to something already classified
• De Novo: devices that aren’t comparable enough to something on the market. This generates a new device classification regulation, and will typically (but not always) be Class II
• Class I: Low risk, general controls are typically sufficient; generally exempt from 510(k)
Regulatory Pathways for Medical Devices

NonClinical & Clinical Study Phase
May occur over multiple years of development

Sponsors submit a presubmission to the FDA to start early regulatory discussions and develop a path forward

Sponsors Apply to FDA to Market Device

PreMarket Approval (PMA) Submission
180* Days

De Novo Submission
120* Days

Premarket Notification 510(k)
90* Days

Humanitarian Device Exemption
75* Days

FDA Decision Points

*Number of days noted is days the submission is under review by the FDA, not the total time that it may take to get the device technology to market or through the review process. In some cases, the review process may take longer depending upon the particular device, technology, indication for use, user, and risk of the device.

Leigh et al., 2016
Reducing FDA Review Timelines

Median Days to Full IDE Study Approval

<table>
<thead>
<tr>
<th>Year</th>
<th>Days to Approval</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY11</td>
<td>442</td>
</tr>
<tr>
<td>FY13*</td>
<td>215</td>
</tr>
<tr>
<td>FY14*</td>
<td>101</td>
</tr>
</tbody>
</table>

FY15 Goal Met: 30

* Values calculated on 10/31/13 and 10/31/14 respectively
PMA Originals & Panel Tracks, Original HDEs, and De Novos FDA Activity

Leigh et al., 2016
Increasing **Regulatory Transparency**

NEW Targeted Guidance for Sponsors (and Developers & Innovators)

• Presubmission Guidance
• IDEs for Early Feasibility Clinical Studies Guidance Document
• Design Considerations for Pivotal Clinical Investigations
• Expedited Access for Premarket Approval Medical Devices Intended for Unmet Medical Need for Life Threatening or Irreversibly Debilitating Diseases or Conditions

**NEW FINAL Guidance - November, 2016**

• Clinical Considerations for IDEs for Neurological Devices Targeting Disease Progression and Clinical Outcomes
Investing in Review: Neurological Device Division at the FDA
Center for Devices and Radiological Health (CDRH) Organization

Division of Neurological and Physical Medicine Devices
# Division of Neurological and Physical Medicine Devices

## New Branch Organization

<table>
<thead>
<tr>
<th>Neurodiagnostic and Neurosurgical Devices</th>
<th>Neurointerventional Devices</th>
<th>Neurostimulation Devices Neurology Branch</th>
<th>Neurostimulation Devices Psychiatry Branch</th>
<th>Physical Medicine &amp; Rehabilitation Devices</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Cranial Materials &amp; Other Sealants</td>
<td>• Embolization Coils</td>
<td>• Stimulation Devices for Movement Disorders, Epilepsy, Alzheimer’s Disease, Headache, and Traumatic Brain Injury</td>
<td>• Stimulation Devices for Major Depression, Obsessive Compulsive Disorder, and Post Traumatic Stress Disorder</td>
<td>• Brain Computer Interfaces</td>
</tr>
<tr>
<td>• EEG &amp; Non-EEG Diagnostic Devices</td>
<td>• Flow Diverters</td>
<td>• Devices may include cortical stimulation devices and deep brain stimulation devices</td>
<td>• Devices may include cranial electrical stimulation devices, electroconvulsive therapy, and transcranial magnetic stimulation devices</td>
<td>• Diathermy</td>
</tr>
<tr>
<td>• Neurocognitive Diagnostic Devices</td>
<td>• Guidewires &amp; Catheters for the Neurovasculature</td>
<td></td>
<td></td>
<td>• Functional Electrical Stimulators</td>
</tr>
<tr>
<td>• Surgical Instruments &amp; Tools for the Neurovasculature</td>
<td>• Neurothrombectomy Devices</td>
<td></td>
<td></td>
<td>• Iontophoresis Devices</td>
</tr>
<tr>
<td>• Stereotactic Systems for the Neurovasculature</td>
<td>• Neurovascular &amp; Cerebral Interventional Devices</td>
<td></td>
<td></td>
<td>• Massagers/Vibrators</td>
</tr>
<tr>
<td></td>
<td>• Cerebrospinal Fluid Shunts</td>
<td></td>
<td></td>
<td>• Orthoses, Exoskeletons</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Powered Muscle Stimulators</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Rehabilitation Equipment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Wheelchairs, Walkers</td>
</tr>
</tbody>
</table>
Pre-Submissions

WHAT: an opportunity to obtain FDA feedback prior to IDE or marketing submission

Guidance Document

“Requests for Feedback on Medical Device Submissions: The Pre-Submission Program and Meetings with Food and Drug Administration Staff”

(Issued February 18, 2014)
NeuroView
FDA Regulation of Neurological and Physical Medicine Devices: Access to Safe and Effective Neurotechnologies for All Americans


NEW FDA website for Neurological Devices: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/NeurologicalDevices/default.htm
## FDA Points of Contact

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Contact Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carlos Peña, PhD MS</td>
<td>Division Director</td>
<td><a href="mailto:Carlos.Pena@fda.hhs.gov">Carlos.Pena@fda.hhs.gov</a></td>
</tr>
<tr>
<td>William Heetderks, MD PhD</td>
<td>Deputy Division Director (Clinical)</td>
<td><a href="mailto:William.Heetderks@fda.hhs.gov">William.Heetderks@fda.hhs.gov</a></td>
</tr>
<tr>
<td>Michael Hoffmann</td>
<td>Deputy Division Director (Regulatory Policy)</td>
<td><a href="mailto:Michael.Hoffmann@fda.hhs.gov">Michael.Hoffmann@fda.hhs.gov</a></td>
</tr>
<tr>
<td>Tim Marjenin</td>
<td>Branch Chief, Neurostimulation Devices Neurology</td>
<td><a href="mailto:Timothy.Marjenin@fda.hhs.gov">Timothy.Marjenin@fda.hhs.gov</a></td>
</tr>
<tr>
<td>John Doucet, PhD</td>
<td>Branch Chief, (acting) Neurostimulation Devices Psychiatry</td>
<td><a href="mailto:John.Doucet@fda.hhs.gov">John.Doucet@fda.hhs.gov</a></td>
</tr>
<tr>
<td>Vivek Pinto, PhD</td>
<td>Branch Chief, Physical Medicine and Rehabilitation Devices</td>
<td><a href="mailto:Vivek.Pinto@fda.hhs.gov">Vivek.Pinto@fda.hhs.gov</a></td>
</tr>
<tr>
<td>Xiaolin Zheng, PhD</td>
<td>Branch Chief, Neurointerventional and Devices</td>
<td><a href="mailto:Xiaolin.Zheng@fda.hhs.gov">Xiaolin.Zheng@fda.hhs.gov</a></td>
</tr>
<tr>
<td>Jay Gupta</td>
<td>Branch Chief, (acting) Neurodiagnostic and Neurosurgical Devices Branch</td>
<td><a href="mailto:Jay.Gupta@fda.hhs.gov">Jay.Gupta@fda.hhs.gov</a></td>
</tr>
</tbody>
</table>